Caribou Biosciences is a clinical-stage biopharmaceutical company focused on advancing allogeneic CAR-T cell therapies using its novel chRDNA genome-editing platform. The company’s pipeline centers on two clinical candidates targeting hematologic malignancies, with regulatory designations supporting expedited development. Despite meaningful operating loss reductions in 2025 driven by cost prioritization, Caribou remains unprofitable and faces ongoing capital needs. Its technological moat lies in enhanced specificity and multiplex editing capabilities that aim to differentiate it from first-generation CRISPR approaches. Market and regulatory risks, including Nasdaq listing compliance challenges and litigation, remain material factors to monitor alongside pivotal clinical trial progressions.